L'Oréal S.A.

L'Oréal S.A.

LRLCY
L'Oréal S.A.US flagOther OTC
85.68
USD
-2.19
- -
228.68BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
7.4
7.81
8.72
8.91
9.31
9.63
10.67
10.01
11.58
14.28
15.38
16.27
16.51
Basic EPS, GAAP
0.99
1.7
1.18
1.11
1.28
1.39
1.34
1.27
1.65
2.13
2.31
2.4
2.3
Free Cash Flow per Basic Share
0.89
0.99
1.1
1.21
1.41
1.39
1.8
1.96
2.03
1.84
2.28
2.49
2.68
Dividend per Share
0.48
0.55
0.55
0.66
0.67
0.74
0.79
0.78
0.84
1
1.28
1.35
1.47
Book Value per Share
1.03
1.74
1.22
1.15
1.32
1.43
1.38
1.31
1.69
2.17
2.35
2.44
2.34
Tangible Book Value per Share
4.8
3.45
4.49
4.48
4.78
5.09
5.96
5.41
3.25
4.41
4.37
5.67
5.79
Basic Weighted Avg Shares
2,989
2,886
2,787
2,796
2,796
2,798
2,799
2,796
2,788
2,679
2,677
2,673
2,669
Sales/Revenue/Turnover
22,124
22,532
24,290
24,916
26,024
26,937
29,874
27,992
32,288
38,261
41,182
43,487
44,052
Operating Margin (%)
17
17.27
17.84
18.08
17.97
18.27
18.57
18.61
19.08
19.49
19.77
19.98
20.19
Depreciation Expense
768
856
908
1,382
1,218
1,109
1,958
2,028
1,781
1,536
1,715
1,855
1,817
Net Income, GAAP
2,958
4,910
3,297
3,106
3,581
3,895
3,750
3,563
4,597
5,707
6,184
6,409
6,127
Effective Tax Rate (%)
26.57
28.56
27.46
28.24
19.07
24.78
30.62
25.33
23.9
24.96
22.63
23.9
27.79
Profit Margin (%)
13.37
21.79
13.58
12.46
13.76
14.46
12.55
12.73
14.24
14.92
15.02
14.74
13.91
Working Capital
3,094
-492
1,080
838
1,846
2,355
3,048
3,430
-4,507
330
1,426
1,838
6,832
LT Debt
84
67
41
31
14
14
1,638
1,303
1,258
4,231
6,141
6,645
9,433
Total Equity
22,651
20,197
23,617
24,504
24,818
26,934
29,426
28,999
23,593
27,186
29,082
33,138
35,004
Return on Invested Capital (%)
11.87
11.53
12.62
12.22
13.87
12.96
12.04
11.54
14.43
17.27
17.22
15.71
13.75
Return on Capital (%)
89.48
89.77
56.47
72.28
77.37
77.5
63.38
55.89
53.68
51.21
48.03
44.61
38.48
Return on Common Equity (%)
97.49
121.21
78.21
93.71
103.63
101.17
95.31
94.56
109.66
108.47
102.18
100.09
96.12

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.45%
4.63%
5.63%
Free Cash Flow
9.45%
6.16%
7.79%
Net Income, GAAP
7.03%
12.15%
-4.39%
Sales/Revenue/Turnover
6.35%
9.68%
1.3%
Total Cash Common Dividend
10.1%
12.59%
8.36%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
41,182
2024
- -
- -
- -
- -
43,487
2025
- -
- -
- -
- -
44,052

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.31
2024
- -
- -
- -
- -
2.4
2025
- -
- -
- -
- -
2.3

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.28
2024
- -
- -
- -
- -
1.35
2025
- -
- -
- -
- -
1.47

Company Description

APIChat
CEO
Nicolas Hieronimus
Full Time Employees
94,397
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
41, rue Martre Clichy France 92117
IPO Date
Apr 18, 2007
Website
loreal.com
Business
L'Oréal S.A. (LRLCY) operates as the world's largest cosmetics company, specializing in beauty products across haircare, skincare, makeup, fragrances, and body care; it organizes its 37 global brands into four divisions: Professional Products, Consumer Products, L'Oréal Luxe, and Dermatological Beauty. The company manufactures and markets an extensive portfolio including hair colorants and styling products such as Kérastase, Redken, and L'Oréal Professionnel; mass-market cosmetics, skincare, and haircare under Garnier, Maybelline New York, L'Oréal Paris, and NYX Professional Makeup; luxury fragrances, makeup, and skincare from Lancôme, Yves Saint Laurent Beauté, Giorgio Armani Beauty, Kiehl's, and Viktor&Rolf; and dermatological beauty solutions like La Roche-Posay, Vichy, SkinCeuticals, and CeraVe. Founded in 1909 and headquartered in Clichy, near Paris, France, L'Oréal conducts research and innovation through 21 global centers, employs over 90,000 people, and distributes its products in more than 150 countries, serving professional salons, mass-market retail, luxury boutiques, pharmacies, and e-commerce channels worldwide. In recent developments, L'Oréal announced in October 2025 a €4 billion strategic partnership with Kering, acquiring the House of Creed fragrance brand and securing 50-year exclusive licenses to develop beauty and fragrance products for Gucci, Bottega Veneta, and Balenciaga, with closing expected in the first half of 2026; earlier in June 2025, it agreed to acquire premium haircare brand Color Wow, and in 2024 expanded through stakes in Korean cosmetics firm Gowoonsesang (Dr.G brand) and a licensing deal with Miu Miu for luxury beauty products, while selling haircare brand Carol's Daughter in March 2025 to refocus its portfolio.

Company News

APIChat
  • KVUE or LRLCY: Which Is the Better Value Stock Right Now?

  • EYE or LRLCY: Which Is the Better Value Stock Right Now?

  • L'Oréal and Adeia Enter Multi-Year License Agreement

  • L'Oreal chairman says Coty lacks business model

  • L'Oreal stock jumps 9% after Q1 earnings: how high can it go?

  • L'Oreal Heiress Fortune Rises By $6 Billion As Company's Shares Soar After Strong Earnings

  • L'Oreal Shares Surge After Sales Rise Despite Tough Market Conditions

  • L'Oreal stock pops 8% after 'impressive' earnings

  • L'Oréal S.A. (LOR:CA) Q1 2026 Sales/Trading Call Transcript

  • Analyzing Newell Brands (NASDAQ:NWL) and L’Oreal (OTCMKTS:LRLCY)

  • L'Oréal completes the acquisition of Kering Beauté within the framework of its strategic alliance with Kering

  • L'Oreal: Looking Interesting Again For Long-Term Investors (Upgrade)

  • Contrasting ARKO (NASDAQ:ARKO) & L’Oreal (OTCMKTS:LRLCY)

  • L'Oréal S.A. (LOR:CA) Presents at Consumer Analyst Group of New York Conference 2026 Prepared Remarks Transcript

  • Market Today: Amazon Overtakes Walmart; Blue Owl Rattles Credit; FDA Eyes Moderna Flu Shot

  • First Look: Walmart beat, Meta trial, FDA eyes Moderna

  • Market Today: Moderna rebounds; oil and gold jump

  • First Look: Nvidia-Meta chip pact, Bayer deal, WBD talks

  • First Look: WBD waiver; Ackman's Meta bet; Ford-China JV

  • L'Oréal S.A. (LOR:CA) Q4 2025 Earnings Call Transcript